bioMérieux – First-Half 2025 Results

Original from: bioMérieux

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on September 3, under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2025.

· +9.4% organic sales growth in H1 25, reaching €2,044 million, driven by a +10% organic sales increase across the four growth drivers of the GO•28 strategic plan and +12% organic sales growth in BIOFIRE® respiratory panels:

 - BIOFIRE® non-respiratory panels: +10% organic growth, a solid performance evenly distributed across all regions;

 - SPOTFIRE®: continued expansion with €79 million in H1 25 sales, marking a +143% organic increase compared to last year;

 - Microbiology: +3% organic sales growth, impacted by a double digit decline in China;

 - Industrial Applications: +10% organic sales growth, supported by a strong mid-teens growth in the Pharma Quality Control segment;

 - BIOFIRE® respiratory panels: +12% organic sales growth, largely driven by the relevance of the solution amid very high epidemiological activity in Q1 25.

· €946 million of sales in Q2 2025, representing a +6.1% like-for-like increase and +8% organic sales growth excluding China

· Contributive operating income before non-recurring items (CEBIT) reached €372  million in H1 25, a remarkable +24% like-for-like evolution versus H1 24. The H1 25 CEBIT margin stands at 18.2% of sales, up +210bps compared to H1 24.

· Net income (group share) amounted to €161m, down 25% compared to H1 2024, impacted by the partial impairment of the Reveal technology.

· Excellent free cash-flow generation at €170 million in H1 25, up more than 3 times compared to H1 2024, driven by EBITDA increase and working capital management.

· Adjustment of the 2025 full year guidance: sales are now expected to grow organically by +6% to +7.5% (initially “at least +7%”) impacted by China market decline and CEBIT is expected to grow by +12% to +18% organically (initially “at least +10%”) driven by improved operating leverage. The 2025 full year currency effect is now expected to be negative in the range of -€25m (previously -€35m to -€40m).

Pierre Boulud, Chief Executive Officer, said: "With a strong increase in profitability in the first half of 2025, bioMérieux confirms the relevance of the GO28 plan in a complex economic and geopolitical environment. At the same time, we have continued to invest in preparing bioMérieux’s future growth through the acquisition of SpinChip Diagnostics - a promising Point-of-Care immunoassays technology – as well as the next-generation sequencing assets from Day Zero Diagnostics.”

Source: bioMérieux – First-Half 2025 Results